caa a22 4500 445330945 CHVBK 20180317142737.0 cr unu---uuuuu 170323e20110901xx s 000 0 eng 10.1007/s10689-011-9434-1 doi (NATIONALLICENCE)springer-10.1007/s10689-011-9434-1 Familial breast cancer: is it time to move from a reactive to a proactive role? [Elektronische Daten] [H. Harris, I. Nippert, C. Julian-Reynier, J. Schmidtke, C. van Asperen, D. Gadzicki, A. Tibben, D. Evans] In 2004 the NICE guidelines on familial breast cancer advised Health Care Professionals that they should not actively seek to identify women with a family history of breast cancer. We have carried out a review of the evidence base and a large scale questionnaire survey of health professionals in four European countries. There is overwhelming support amongst GPs and surgeons against the premise that that health care professionals should not be proactive in identifying patients at risk of familial breast cancer. This that suggest the time is right to overturn the NICE decision. Springer Science+Business Media B.V., 2011 BRCA1 nationallicence BRCA2 nationallicence Breast cancer nationallicence Screening nationallicence Mortality nationallicence Proactive nationallicence Harris H. GenEd Coordinating Centre, University of Manchester, Manchester, UK aut Nippert I. Women's Health Research, Westfaelische Wilhelms-Universitaet, Münster Medical School, Münster, Germany aut Julian-Reynier C. U912, INSERM, IRD, Aix-Marseille Université, Institut Paoli- Calmettes, Marseille, France aut Schmidtke J. Institute of Human Genetics, Hannover Medical School, Hannover, Germany aut van Asperen C. Department of Clinical Genetics, Centre for Human and Clinical Genetics, Leiden University Medical Centre (LUMC), Leiden, The Netherlands aut Gadzicki D. Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany aut Tibben A. Centre of Human and Clinical Genetics, Leiden University Medical Centre (LUMC), Leiden, The Netherlands aut Evans D. Genetic Medicine MAHSC, Central Manchester University Hospitals NHS Foundation Trust, St Mary's Hospital, Manchester, UK aut Familial Cancer Springer Netherlands 10/3(2011-09-01), 501-503 1389-9600 10:3<501 2011 10 10689 https://doi.org/10.1007/s10689-011-9434-1 text/html Onlinezugriff via DOI 1 brief-communication jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10689-011-9434-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Harris H. GenEd Coordinating Centre, University of Manchester, Manchester, UK aut NATIONALLICENCE 700 1- Nippert I. Women's Health Research, Westfaelische Wilhelms-Universitaet, Münster Medical School, Münster, Germany aut NATIONALLICENCE 700 1- Julian-Reynier C. U912, INSERM, IRD, Aix-Marseille Université, Institut Paoli- Calmettes, Marseille, France aut NATIONALLICENCE 700 1- Schmidtke J. Institute of Human Genetics, Hannover Medical School, Hannover, Germany aut NATIONALLICENCE 700 1- van Asperen C. Department of Clinical Genetics, Centre for Human and Clinical Genetics, Leiden University Medical Centre (LUMC), Leiden, The Netherlands aut NATIONALLICENCE 700 1- Gadzicki D. Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany aut NATIONALLICENCE 700 1- Tibben A. Centre of Human and Clinical Genetics, Leiden University Medical Centre (LUMC), Leiden, The Netherlands aut NATIONALLICENCE 700 1- Evans D. Genetic Medicine MAHSC, Central Manchester University Hospitals NHS Foundation Trust, St Mary's Hospital, Manchester, UK aut NATIONALLICENCE 773 0- Familial Cancer Springer Netherlands 10/3(2011-09-01), 501-503 1389-9600 10:3<501 2011 10 10689 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer